Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2024-11-11 Share Issue/Capital Cha…
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - MSB 6 pages 20.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance of unquoted securities (warrants) by Mesoblast Limited. It references previous announcements (Appendix 3B) and provides specifics such as the number of securities issued, issue date, exercise price, and other terms. The document is a formal notification to the ASX about securities issuance, not a financial report, earnings release, or management discussion. It fits the description of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document length is 6943 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-11-11 English
Warrant Prospectus Related to Convertible Note Agreement 47 pages 746.5KB
Capital/Financing Update Classification · 95% confidence The document is titled as a 'Prospectus for Issue of Warrants' related to a convertible note subscription agreement. It details the offer of warrants to an investor, including terms, conditions, risk factors, and legal notices. The document is a formal offering document prepared in accordance with the Corporations Act and lodged with ASIC. It is not a financial report, earnings release, or management discussion, but a legal and regulatory document for a securities offering. This fits the definition of a Prospectus related to capital raising activities, which aligns with the category 'Capital/Financing Update (CAP)'. The document is lengthy (15,000 characters) and contains substantive information about the offer, not merely an announcement or a brief summary, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2024-11-06 English
Ceasing to be a substantial holder 26 pages 1.4MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001 Section 671B. It details changes in relevant interests of JPMorgan Chase & Co. and its affiliates in the voting securities of Mesoblast Ltd, including transaction dates, quantities, and prices. This type of filing is a notification of changes in significant share ownership levels, specifically when a substantial holder ceases to hold that status. It is not a financial report, earnings release, or management report, but a regulatory notification about shareholding changes. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief announcement but a detailed notification, supporting high confidence.
2024-11-04 English
6-K
Regulatory Filings
2024-11-01 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 537.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED SEPTEMBER 30, 2024' and contains detailed financial and operational information for the quarter ended September 30, 2024. It includes financial highlights such as cash balance, net operating cash spend, and cost control measures, as well as operational updates on clinical trials and regulatory interactions. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content aligns with a comprehensive quarterly financial and operational report, which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, nor is it a full annual report or earnings release. Therefore, the appropriate classification is IR with high confidence.
2024-10-30 English
6-K
Regulatory Filings
2024-10-18 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.